Siemens invests in MI firm

Article

VisEn Medical, a developer of agents and systems in the field of molecular imaging, has a new partner. Siemens has taken an equity stake in the company in an effort to promote the development of MI technology and expand the markets for in vivo imaging of

VisEn Medical, a developer of agents and systems in the field of molecular imaging, has a new partner. Siemens has taken an equity stake in the company in an effort to promote the development of MI technology and expand the markets for in vivo imaging of molecular events. VisEn, which was founded in June 2000 on technologies developed at Massachusetts General Hospital and Harvard Medical School, is focusing on technology for imaging cancer, atherosclerosis, and rheumatoid arthritis.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.